Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,711 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The amyloid-β pathway in Alzheimer's disease: a plain language summary.
Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. Hampel H, et al. Among authors: perry g. Neurodegener Dis Manag. 2023 Jun;13(3):141-149. doi: 10.2217/nmt-2022-0037. Epub 2023 Mar 30. Neurodegener Dis Manag. 2023. PMID: 36994753 Free PMC article. Review.
Precision pharmacology for Alzheimer's disease.
Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. Among authors: perry g. Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16. Pharmacol Res. 2018. PMID: 29458203 Free PMC article. Review.
Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study.
Teipel SJ, Cavedo E, Lista S, Habert MO, Potier MC, Grothe MJ, Epelbaum S, Sambati L, Gagliardi G, Toschi N, Greicius MD, Dubois B, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Teipel SJ, et al. Alzheimers Dement. 2018 Sep;14(9):1126-1136. doi: 10.1016/j.jalz.2018.04.004. Epub 2018 May 21. Alzheimers Dement. 2018. PMID: 29792873
Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers.
Vergallo A, Bun RS, Toschi N, Baldacci F, Zetterberg H, Blennow K, Cavedo E, Lamari F, Habert MO, Dubois B, Floris R, Garaci F, Lista S, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Alzheimers Dement. 2018 Dec;14(12):1623-1631. doi: 10.1016/j.jalz.2018.06.3053. Epub 2018 Jul 26. Alzheimers Dement. 2018. PMID: 30055132 Free article.
Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints.
Cavedo E, Chiesa PA, Houot M, Ferretti MT, Grothe MJ, Teipel SJ, Lista S, Habert MO, Potier MC, Dubois B, Hampel H; INSIGHT-preAD Study Group; Alzheimer Precision Medicine Initiative (APMI). Cavedo E, et al. Alzheimers Dement. 2018 Sep;14(9):1204-1215. doi: 10.1016/j.jalz.2018.05.014. Epub 2018 Jul 7. Alzheimers Dement. 2018. PMID: 30201102 Review.
Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study.
Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert MO, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H; for the INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Sakr FA, et al. Alzheimers Res Ther. 2019 Jan 31;11(1):15. doi: 10.1186/s13195-019-0466-3. Alzheimers Res Ther. 2019. PMID: 30704537 Free PMC article.
The Alzheimer Precision Medicine Initiative.
Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. Among authors: perry g. J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121. J Alzheimers Dis. 2019. PMID: 30814352 Review.
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.
Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18. Alzheimers Dement. 2019. PMID: 31113759
1,711 results